Yu Noda

915 total citations
40 papers, 535 citations indexed

About

Yu Noda is a scholar working on Hepatology, Surgery and Oncology. According to data from OpenAlex, Yu Noda has authored 40 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 12 papers in Surgery and 12 papers in Oncology. Recurrent topics in Yu Noda's work include Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Cancer Mechanisms and Therapy (8 papers). Yu Noda is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers) and Cancer Mechanisms and Therapy (8 papers). Yu Noda collaborates with scholars based in Japan. Yu Noda's co-authors include Takashi Niizeki, Hironori Koga, Masahito Nakano, Ryoko Kuromatsu, Hideki Iwamoto, Takuji Torimura, Shigeo Shimose, Tomotake Shirono, Naoki Kamachi and Shusuke Okamura and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Oncotarget.

In The Last Decade

Yu Noda

38 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu Noda Japan	14	353	176	165	163	138	40	535
Eleonora Terzi Italy	12	530 1.5×	84 0.5×	168 1.0×	309 1.9×	102 0.7×	22	660
Martin W. James United Kingdom	10	457 1.3×	130 0.7×	188 1.1×	313 1.9×	159 1.2×	23	640
Alexandra Heurgué France	7	322 0.9×	153 0.9×	101 0.6×	174 1.1×	62 0.4×	17	506
Marc Puigvehí Spain	11	358 1.0×	120 0.7×	94 0.6×	266 1.6×	75 0.5×	24	515
Hiroaki Nagamatsu Japan	12	388 1.1×	79 0.4×	126 0.8×	218 1.3×	88 0.6×	32	517
Kensaku Sanefuji Japan	15	380 1.1×	147 0.8×	334 2.0×	171 1.0×	33 0.2×	29	611
Ryusuke Yamaguchi Japan	4	339 1.0×	126 0.7×	234 1.4×	161 1.0×	48 0.3×	5	504
Marian M. Claessen Netherlands	6	251 0.7×	88 0.5×	240 1.5×	162 1.0×	41 0.3×	8	475
Hiromitsu Kumada Japan	9	368 1.0×	125 0.7×	247 1.5×	236 1.4×	36 0.3×	22	583

Countries citing papers authored by Yu Noda

Since Specialization

Citations

This map shows the geographic impact of Yu Noda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Noda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Noda more than expected).

Fields of papers citing papers by Yu Noda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Noda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Noda. The network helps show where Yu Noda may publish in the future.

Co-authorship network of co-authors of Yu Noda

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Noda. A scholar is included among the top collaborators of Yu Noda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Noda. Yu Noda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2024). Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. Current Oncology. 31(10). 5821–5831. 1 indexed citations

Iwamoto, Hideki, Takashi Niizeki, Tomotake Shirono, et al.. (2024). Case Reports of Pituitary Adrenocortical Insufficiency Following Atezolizumab+Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Kanzo. 65(1). 37–44.

Shimose, Shigeo, Takashi Niizeki, Hideki Iwamoto, et al.. (2023). Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib. Journal of Gastroenterology and Hepatology. 38(7). 1140–1147. 4 indexed citations

Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, et al.. (2023). Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching. International Journal of Molecular Sciences. 24(18). 13715–13715. 4 indexed citations

Shimose, Shigeo, Hideki Iwamoto, Tomotake Shirono, et al.. (2023). The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Medicine. 12(11). 12325–12335. 14 indexed citations

Shirono, Tomotake, Hideki Iwamoto, Takashi Niizeki, et al.. (2022). Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology Communications. 6(9). 2594–2604. 8 indexed citations

Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2022). Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers. 14(17). 4284–4284. 11 indexed citations

Kuromatsu, Ryoko, Tatsuya Ide, Shusuke Okamura, et al.. (2022). Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers. 14(9). 2295–2295. 5 indexed citations

Nakano, Masahito, Kazuta Fukumori, Yoichi Yano, et al.. (2021). Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers. 13(21). 5282–5282. 12 indexed citations

10.

Shirono, Tomotake, Hironori Koga, Takashi Niizeki, et al.. (2021). Usefulness of a novel transarterial chemoinfusion plus external‐beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study. Cancer Reports. 5(8). e1539–e1539. 5 indexed citations

11.

Kamachi, Naoki, Masahito Nakano, Shusuke Okamura, et al.. (2021). Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound. Cancer Reports. 5(2). e1471–e1471. 6 indexed citations

12.

Iwamoto, Hideki, Shigeo Shimose, Yu Noda, et al.. (2021). Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 13(11). 2786–2786. 39 indexed citations

13.

Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2021). Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers. 13(1). 160–160. 37 indexed citations

14.

Niizeki, Takashi, Hideki Iwamoto, Tomotake Shirono, et al.. (2021). Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers. 13(17). 4450–4450. 15 indexed citations

15.

Shirono, Tomotake, Takashi Niizeki, Hideki Iwamoto, et al.. (2021). Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine. 10(5). 987–987. 4 indexed citations

16.

Suzuki, Hiroyuki, Hideki Iwamoto, Masahito Nakano, et al.. (2021). Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Translational Oncology. 14(11). 101201–101201. 4 indexed citations

17.

Nakano, Masahito, Ryoko Kuromatsu, Takashi Niizeki, et al.. (2020). Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis. Hepatology Communications. 4(8). 1218–1228. 18 indexed citations

18.

Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, et al.. (2020). Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers. 12(7). 1867–1867. 54 indexed citations

19.

Iwamoto, Hideki, Hiroyuki Suzuki, Shigeo Shimose, et al.. (2020). Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers. 12(4). 1010–1010. 44 indexed citations

20.

Noda, Yu, Takumi Kawaguchi, Masaaki Korenaga, et al.. (2019). High serum interleukin‐34 level is a predictor of poor prognosis in patients with non‐viral hepatocellular carcinoma. Hepatology Research. 49(9). 1046–1053. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact